Search | SciELO

Need help?

Add field +

Search history

No documents were found for your search

Results: 32

au:Giorgi, Mariano A

Filters

Collection + Options

All
Argentina

26
Mexico

2
Chile

1
SciELO Preprints

1
Brazil

1
Public Health

1

Journal + Options

All
Revista argentina de cardiología

20
Medicina (Buenos Aires)

5
Archivos de cardiología de México

2
Arquivos Brasileiros de Cardiologia

1
Revista Panamericana de Salud Pública

1
Revista de la Sociedad Argentina de Diabetes

1
Revista médica de Chile

1

Language

All
Portuguese

1

Publication Year + Options

All
2008

4
2009

3
2012

3
2014

3
2015

3
2020

3
2021

3
2011

2
2023

2
2005

1
2006

1
2007

1
2013

1
2017

1
2022

1

Show all...

SciELO Thematic Areas

All
Health Sciences

31

WoS Subject Categories + Options

All
Cardiac

23
Cardiovascular

23
Systems

23
General

7
Internal

7
Medicine

7
Health

1
Policy

1
Services

1

WoS Citation Index

All
Science Citation Index Expanded

7

Citables and non citables + Options

All
Citable

26
Non citable

5

Type of Literature + Options

All
Article

24
Brief report

2
Editorial

2
Abstract

1
Letter

1
Review article

1
Other

1

Order by

Page of 3 Next

Select this page

Print | Send to email | Export |

Facebook
Twitter
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

0 Selected itens

List all
Erase all

Mortalidad y consumo de tabaco: el método del riesgo atribuible poblacional como una herramienta de estimación del daño
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Giorgi, Mariano A.

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

oct 2023, Volume 91 N. 3 Pages 182 - 183

Abstract: Es | Text: Es | PDF: Es

https://doi.org/10.7775/rac.es.v91.i3.20644

Mortality and Tobacco Consumption: the Population Attributable Fraction Method as a Tool to Estimate Damage
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Giorgi, Mariano A.

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

oct 2023, Volume 91 N. 3 Pages 250 - 251

Abstract: En | Text: En | PDF: En

https://doi.org/10.7775/rac.v91.i3.20644

Relación entre enfermedad cardiovascular y renal en una muestra de pacientes con diabetes del mundo real
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Salmeri, Emiliano

; Elbert, Alicia

; Lavalle-Cobo, Augusto

; Aranguren, Florencia

; Sanabria, Hugo

; Giorgi, Mariano

; Forte, Ezequiel

Archivos de cardiología de México

Journal Metrics
- Sobre o periódico
- SciELO Analytics

jun 2022, Volume 92 N. 2 Pages 165 - 173

Abstract: En Es | Text: En Es | PDF: En | PDF: Es

Abstract Objectives: Kidney disease is one of the microvascular complications of diabetes mellitus (DM) with little research and a strong association with cardiovascular disease (CVD). The objective of this study is to characterize the prevalence of kidney disease in a population of patients with type 2 diabetes who attend outpatient control by cardiology, to evaluate its degree of investigation and whether its presence impacts on the achievement of therapeutic goals and use of antidiabetics with cardiovascular and kidney protective effect. Methods: Cross-sectional, observational and multicenter study, carried out in 44 centers in Argentina between May and July 2019. Results: A population with 693 patients with DM was included. The prevalence of CVD was 47.5% (329 patients) and that of microvascular disease was 42.3%. Albuminuria was evaluated only in 46.2% of the patients and was significantly higher in the group with renal impairment (RI). The presence of CVD in patients with RI was greater than in those without RI (64.8% vs. 42.2%; p = 0.0001). The presence of albuminuria was associated with a higher prevalence of CVD. The achievement of therapeutic goals was scarce and no differences were evidenced based on the presence of RI, except for the LDL goal. Low prescription of antidiabetic drugs with proven cardiovascular and kidney benefit was observed. Conclusions: This study highlights the importance of the active search for kidney disease in patients with DM, exposing the low scope of therapeutic goals and the prescription of antidiabetic drugs with cardiovascular and kidney benefit.

Resumen Objetivos: La enfermedad renal es una de las complicaciones microvasculares de la diabetes mellitus (DM) con escasa pesquisa y gran relación con enfermedad cardiovascular (ECV). El objetivo de este trabajo es caracterizar la prevalencia de enfermedad renal en una población de pacientes con diabetes tipo 2 que concurren a control ambulatorio por cardiología, determinar su grado de pesquisa y su posible efecto en el alcance de los objetivos terapéuticos y en el uso de los antidiabéticos con efecto protector cardiorrenal. Métodos: Estudio de corte transversal, observacional y multicéntrico realizado en 44 centros de Argentina entre mayo y julio de 2019. Resultados: Se incluyó a 693 pacientes con una prevalencia de ECV establecida de 47.5% (329 pacientes) y de enfermedad microvascular de 42.3%. La albuminuria se valoró sólo en el 46.2% de los pacientes y fue significativamente mayor en el grupo con IR. La ECV en pacientes con IR fue mayor que en aquéllos sin IR (64.8% vs. 42.2%; p = 0.0001). La presencia de albuminuria se acompañó de mayor prevalencia de ECV. El alcance de los objetivos terapéuticos fue escaso y no se reconocieron diferencias en función de la IR, a excepción del objetivo de LDL. Se observó baja prescripción de fármacos antidiabéticos con probado beneficio cardiorrenal. Conclusiones: El trabajo resalta la importancia de la búsqueda activa de la enfermedad renal en pacientes con diabetes, lo que revela el bajo alcance de los objetivos terapéuticos y la prescripción de fármacos antidiabéticos con beneficio cardiorrenal.

https://doi.org/10.24875/acm.20000566 69 downloads

Extrañando a Raúl.
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

HERSHSON, ALEJANDRO R.

; HIGA, CLAUDIO

; GIORGI, MARIANO

; DI TORO, DARÍO

; THIERER, JORGE

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

apr 2021, Volume 89 N. 2 Pages 163 -

Abstract: Es | Text: Es | PDF: Es

https://doi.org/10.7775/rac.es.v89.i2.20230 11 downloads

El costo del tratamiento: los Reyes Magos son los padres
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

GIORGI, MARIANO A.

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2021, Volume 89 N. 1 Pages 67 - 67

Abstract: Es | Text: Es | PDF: Es

https://doi.org/10.7775/rac.es.v89.i1.19831 34 downloads

Consenso de manejo del paciente con diabetes mellitus y patología cardiovascular. Sociedad Argentina de Cardiología (SAC)-Sociedad Argentina de Diabetes (SAD)
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Giorgi, Mariano Aníbal

; Litwak, León E.

; Sanabria, Hugo

; Lavalle Cobo, Augusto

; Musso, Carla

; Salmeri, Emiliano

; Álvarez, José

; Aranguren, Florencia

; Belcastro, Fernando

; Brites, Fernando

; Buso, Carlos

; Calvagno, Marta

; Caroli, Christian

; Celano, Leonardo

; Cohen Arazi, Hernán

; Comtesse, Daniel

; Corral, Pablo

; Costabel, Juan Pablo

; Elbert, Alicia

; Faingold, Cristina

; Fuente, Graciela

; García Merletti, Pablo

; Giorgi, Mariano Aníbal

; Giunta, Gustavo

; Gómez Santamaría, Héctor

; González Naya, Enrique

; Hadid, Claudio

; Kraselnik, Ariel

; Lavalle Cobo, Augusto

; Litwak, León

; Lobo, Martín

; Lozada, Alfredo

; Majul, Claudio

; Masson, Walter

; Musso, Carla

; Nogueira, Juan

; Persi, Gabriel

; Rodríguez, Martín

; Salmeri, Emiliano

; Sanabria, Hugo

; Schraier, Silvio

; Sinay, Isaac

; Siniawski, Daniel

; Thierer, Jorge

; Salzberg, Susana

; Suárez Cordo, Cristian

; Lerman, Jorge

; Sosa Liprandi, Álvaro

Revista de la Sociedad Argentina de Diabetes

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2021, Volume 55 Suppl. 1 Pages 3 - 70

Abstract: Es En | Text: Es En | PDF: Es | PDF: En

resumen está disponible en el texto completo

Abstract This Consensus comes to light in the midst of one of the worst global health crises in the last 100 years. SARS-CoV-2 and its clinical manifestation, COVID-19, have caused a disruption in how doctors and patients interact. Although it is an infectious disease, one of the most notable characteristics is that its mortality increases in patients with chronic non-communicable diseases and, in particular, with a history of diabetes and cardiovascular disease. In this context, then, we believe that the recommendations made in this document, which aim to identify and protect these patients, become more relevant, while the implementation, beyond the statements, of specific cardiometabolic prevention policies becomes a priority. Methodology: this consensus is the result of the will of two Scientific Societies that have recognized the need to complement the focus on the same problem: that of patients with diabetes mellitus (DM) and cardiovascular disease (CVD), or who are at risk to suffer it. Both the Argentine Society of Cardiology (SAC) and the Argentine Society of Diabetes (SAD) have a recognized track record in the production of practice guidelines and consensus documents, although each has different work practices and cultures. Consequently, the first task that was faced was to agree, not only on the agenda and the approach to the different issues, but also on common working methods: general objective of the document, how to analyze and evalua-te the weight of the information, define the levels of evidence and determine the degrees of recommendation. It was agreed to adopt the modality used by the SAC in all the documents produced by the Consensus and Standards Area, set out in the following table: The experts who collaborated in the drafting of the Consensus were selected and invited to participate with the unanimous agreement of the group of Directors and Secretaries belonging to both Scientific Societies. Colleagues with recognized experience in the disciplines addressed were summoned to analyze the evidence and write the recommendations. All the methodological aspects and the final recommendations of this document were defined by agreement between the group of Directors and Consensus Secretaries.The information consolidation process was slow: from the decision of both companies until the writing of this document, the field of DM and CVD management underwent profound transformations that transcend the appearance of new therapeutic agents. What has been developed is a new approach model that is, in the words of Dr. Alicia Elbert, transdisciplinary. This has implied waiting and being able to understand and "process" all the information that has emerged in these years. This document, which aims to assist physicians in daily practice, has tried to adopt this new integrative perspective.

Características clínicas y control cardiometabólico de personas con diabetes en el consultorio de cardiología en la República Argentina
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

FORTE, EZEQUIEL HERNÁN

; BUSO, CARLOS JAVIER

; DUCZYNSKI, PAULA

; COBO, AUGUSTO LAVALLE

; HARWICZ, PAOLA

; GIORGI, MARIANO

; SALMERI, EMILIANO

; BERENSTEIN, CÉSAR DAMIÁN

; LESCANO, ADRIÁN

; SANABRIA, HUGO

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

nov 2020, Volume 88 N. 6 Pages 517 - 524

Abstract: En Es | Text: En Es | PDF: En | PDF: Es

ABSTRACT Background: Cardiology has a leading role in the control and treatment of persons with type 2 diabetes mellitus (DM2). We do not have local epidemiological data about patients with DM2 treated by cardiologists. Objectives: The aim of this study was to evaluate the clinical characteristics, cardiovascular disease (CVD) and treatment of patients with DM2 attending a cardiology office. Methods: We conducted and observational study in 17 provinces of Argentina during three months. Results: A total of 694 patients were included in the study. Mean age was 64.7±10.5 years, time of disease progression 10.7±9.3 years, body mass index 32±5.9 kg/m2, HbA1c 7.3%±1.6, and blood pressure 135/80 mm Hg. Seventy percent of the patients presented two or more risk factors, 48.1% had CVD and microvascular disease was present in 40.9% of cases (kidney disease in 31.4%, retinopathy in 10.5%, neuropathy in 8.3% and diabetic foot in 3.3%). Patients were receiving antiplatelet agents in 57.3% of cases, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) in 84.3% and 79.5% were treated with statins. Hypoglycemic agents included metformin in 85.9% of patients, dipeptidyl peptidase 4 (DPP4) inhibitors in 24.1%, sulfonylureas (SU) in 14.3%, sodium-glucose co-transporter 2 (SGLT2) inhibitors in 9.8%, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in 3% and glitazones in 1.3%. HbA1C levels ≤7% were achieved by 55.9% of patients, BP <140/90 mm Hg by 61.7%, and LDL-C <100 mg/dL by 58.5% and <70 mg/dL by 28.5%. Conclusions: Most patients with DM2 presented two or more cardiovascular risk factors and a high prevalence of associated complications. Treatment goals were achieved by a low number of patients and the use of medications with demonstrated cardiovascular benefit was low.

RESUMEN Introducción: La cardiología tiene un rol protagónico en el control y el tratamiento de las personas con diabetes mellitus tipo 2 (DM2). No contamos con datos epidemiológicos locales acerca de los pacientes con DM2 asistidos por la especialidad. Objetivos: Evaluar las características clínicas, enfermedad cardiovascular (ECV) y tratamiento de personas con DM2 en el consultorio de cardiología. Material y métodos: Se realizó un estudio observacional en 17 provincias de la Argentina durante 3 meses. Resultados: Se incluyeron 694 pacientes. La edad media fue de 64.7 ± 10.5 años, con un tiempo de evolución de la DM2 de 10.7 ± 9.3 años, índice de masa corporal de 32 ± 5,9 kg/m2, HbA1c de 7,3 ± 1,6 % y tensión arterial 135/80 mmHg. El 70% de los pacientes presentaba 2 o más factores de riesgo. El 48,1% presentaba ECV y el 40,9% enfermedad microvascular (31,4% nefropatía, 10,5% retinopatía, 8,3% neuropatía, 3,3% pie diabético). El 57,3% se encontraban con antiagregantes, 84,3% con inhibidores del sistema renina/angiotensina/aldosterona (iECAS/ARAII), 79,5% con estatinas. Asimismo, el 85,9% recibía metformina, seguido de inhibidores de la dipeptidil peptidasa-4 (iDDP4) (24,1%), insulina (22,2%), sulfonilureas (SU) (14,3%), inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) (9,8%), agonistas del receptor glucagón like (arGLP1) (3%) y glitazonas (1,3%). El 55,9% tenía HbA1c < = 7%, 61,7% TA <140/90 mmHg, 58,5% LDL <100 mg/dl y 28,5% LDL <70 mg/dl. Conclusiones: La mayoría de los pacientes con DM2 presentaba dos o más factores de riesgo cardiovasculares y una elevada prevalencia de complicaciones asociadas. Observamos un bajo alcance de los objetivos terapéuticos, así como también un bajo uso de fármacos con beneficio cardiovascular.

https://doi.org/10.7775/rac.es.v88.i6.18201 214 downloads

[SciELO Preprints] - Clinical Management Strategies in Mild COVID-19 cases in Latin-America: A Decision Model
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Boissonnet, Carlos P. Giorgi, Mariano A. Carosella, Lucila Brescacín, Carola Pissinis, Jerónimo Guetta, Javier N.

Journal Metrics
- Sobre o periódico
- SciELO Analytics

Publication date: 2020-06-02

Abstract: En Es

COVID-19 pandemic is challenging Latin American health systems, which could benefit from information to make appropriate decisions in contexts of constrained health resources.Objective: to evaluate, in adult patients with suspected mild clinical forms of COVID-19, the clinical effectiveness (life expectancy) and resource consumption (days of hospitalization) of different management strategies.Methods: stochastic decision tree comparing the conventional strategy recommended by WHO - PAHO (diagnostic test for COVID-19 and hospitalization of patients testing positive) versus two alternative strategies (immediate addition of a prognostic test with hospitalization according to its result, or follow-up with hospitalization only in case of clinical deterioration).Results: the alternative management strategies showed expected clinical utility similar to the conventional strategy in 80 years-old base cases, and slightly lower in 60 years- and 40 years-old base cases, with lower consumption of hospitalization days. In sensitivity analysis, alternative strategies comparatively improved their expected clinical utility given a lower sensitivity of the diagnostic test or a higher ability of the follow-up to detect clinical worsening.Conclusions: in cases of suspected COVID-19 without pneumonic infiltrate or signs of severity, alternative strategies can be considered to avoid hospitalization for the majority of patients, especially if efficient follow-up modalities can be implemented. This information is valuable for health decision-makers, to carefully weight clinical and epidemiological elements and design locally feasible strategies.

La pandemia COVID-19 desafía los sistemas de salud de Latinoamérica, que podrían beneficiarse de información para tomar decisiones apropiadas, en contextos de escasez de recursos sanitarios.Objetivo: evaluar, en pacientes adultos con sospecha de formas clínicas leves de COVID-19, la efectividad clínica (expectativa de vida) y el consumo de recursos (días de hospitalización) de distintas estrategias de manejo. Métodos: árbol de decisión estocástico, comparando la estrategia convencional recomendada por OMS - OPS (prueba diagnóstica para COVID-19 y hospitalización ante resultado positivo) versus dos estrategias alternativas (agregado inmediato de una prueba pronóstica con hospitalización según ese resultado, y seguimiento con hospitalización sólo ante empeoramiento clínico). Resultados: las estrategias de manejo alternativas mostraron utilidad clínica esperada similar a la estrategia convencional en casos base de 80 años de edad, y ligeramente inferior en casos base de 60 años y 40 años de edad, con menor consumo de días de hospitalización. En el análisis de sensibilidad, las estrategias alternativas mejoraron comparativamente su utilidad clínica esperada si la sensibilidad de la prueba diagnóstica fuera menor o la capacidad del seguimiento para detectar empeoramiento clínico fuera mayor. Conclusiones: ante casos sospechosos de COVID-19 sin infiltrado neumónico ni signos de gravedad, pueden considerarse estrategias que eviten la hospitalización de la mayoría de los pacientes, en especial si pueden implementarse modalidades de seguimiento eficientes. Esta información es valiosa para los decisores en salud, para analizar ponderadamente elementos clínicos y epidemiológicos y diseñar estrategias factibles localmente.

https://doi.org/10.1590/SciELOPreprints.681

Eficacia, seguridad y aplicabilidad clínica de los inhibidores de la PCSK9
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

MASSON, WALTER

; GIORGI, MARIANO

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2020, Volume 88 N. 2 Pages 153 - 163

Abstract: En Es | Text: En Es | PDF: En | PDF: Es

SUMMARY Proprotein convertase subtilisin kexin type 9 (iPCSK9) inhibitors represent a new group of lipid-lowering drugs that have generated a substantial change in lipid management. In a few years, a large number of studies have evaluated the lipid efficacy and safety of these drugs. More recently, large randomized clinical trials showed that the decrease in LDL-C achieved with these drugs was associated with a lower incidence of cardiovascular events. Such evidence resulted in the approval and commercialization of iPCSK9 in many countries. Consequently, various scientific societies and health reference agencies incorporated these drugs into the therapeutic arsenal of dyslipidemia, with the aim of reducing residual cardiovascular risk. In this review, we will describe the efficacy and safety of these drugs, analyze the available evidence about cardiovascular benefit, and discuss in which population their use might be most effective.

RESUMEN Los inhibidores de la proproteína convertasa subtilisina kexina tipo 9 (iPCSK9) representan un nuevo grupo de fármacos hipolipemiantes, que han generado un cambio sustancial en el manejo clínico de los lípidos. En pocos años, una gran cantidad de estudios han evaluado la eficacia antilipídica y la seguridad de estos fármacos. Más recientemente, grandes ensayos clínicos aleatorizados demostraron que el descenso del C-LDL alcanzado con estos fármacos se asoció con una menor incidencia de eventos cardiovasculares. Dicha evidencia dio lugar a la aprobación y comercialización de los iPCSK9 en muchos países. En consecuencia, diversas sociedades científicas y organismos de referencia en salud incorporaron estos fármacos en el arsenal terapéutico de la dislipidemia, con el objetivo de reducir el riesgo cardiovascular residual. En esta revisión describiremos la eficacia y la seguridad de estos fármacos, analizaremos la evidencia disponible acerca del beneficio cardiovascular y discutiremos en qué población podría ser más efectiva su utilización.

https://doi.org/10.7775/rac.es.v88.i2.17470 126 downloads

10.

Variación temporal del tabaquismo en médicos argentinos. Comparación entre los estudios TAMARA I (2004) y II (2013)
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

ZYLBERSZTEJN, HORACIO M.

; LOBO, LORENZO M.

; MASSON, WALTER

; MOLINERO, GRACIELA

; ÁNGEL, ADRIANA

; MULASSI, ANDRÉS

; GIORGI, MARIANO A.

; GARCÍA AURELIO, MAURO

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

feb 2017, Volume 85 N. 1 Pages 1 - 2

Abstract: Es | Text: Es | PDF: Es

28 downloads

11.

Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Masson, Walter

; Siniawski, Daniel

; Lobo, Martín

; Molinero, Graciela

; Giorgi, Mariano

; Huerín, Melina

Arquivos Brasileiros de Cardiologia

Journal Metrics
- Sobre o periódico
- SciELO Analytics

jul 2015, Volume 105 N. 1 Pages 11 - 19

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

Fundamento:Estudos prévios sugerem uma relação linear entre o LDL-C e mudanças no volume de placa coronariana (VPC) medido por ultrassonografia intravascular. No entanto, estas publicações incluíram um número pequeno de estudos e não exploraram outros marcadores lipídicos.Objetivo:Avaliar a associação entre alterações nos marcadores lipídicos e regressão no VPC com base em dados publicados.Métodos:Nós coletamos dados dos braços controle, placebo e intervenção de estudos que compararam o efeito de tratamentos hipolipemiantes no VPC, e dos braços placebo e controle de estudos que testaram medicamentos que não afetam os lipídios. Os volumes inicial e final da placa, representados em mm3, foram extraídos e as alterações percentuais após as intervenções foram calculadas. Nós realizamos três análises de regressão linear e avaliamos a relação entre alterações percentuais e absolutas dos marcadores lipídicos com as variações percentuais do VPC.Resultados:Vinte e sete estudos foram selecionados. As correlações entre as variações percentuais do LDL-C, não- HDL-C e apolipoproteína B (ApoB) com variações percentuais do VPC foram moderadas (r = 0,48; r = 0,47; e r = 0,44, respectivamente). As correlações entre diferenças absolutas do LDL-C, não-HDL-C e ApoB com diferenças percentuais do VPC foram mais fortes (r = 0,57; r = 0,52; e r = 0,79). O modelo de regressão linear mostrou uma associação estatisticamente significativa entre a redução nos marcadores lipídicos e regressão no volume da placa.Conclusão:Observamos uma associação significativa entre alterações de diferentes partículas aterogênicas e regressão do VPC. A redução absoluta da ApoB mostrou a correlação mais forte com a regressão da placa coronariana.

Background:Previous reports have inferred a linear relationship between LDL-C and changes in coronary plaque volume (CPV) measured by intravascular ultrasound. However, these publications included a small number of studies and did not explore other lipid markers.Objective:To assess the association between changes in lipid markers and regression of CPV using published data.Methods:We collected data from the control, placebo and intervention arms in studies that compared the effect of lipidlowering treatments on CPV, and from the placebo and control arms in studies that tested drugs that did not affect lipids. Baseline and final measurements of plaque volume, expressed in mm3, were extracted and the percentage changes after the interventions were calculated. Performing three linear regression analyses, we assessed the relationship between percentage and absolute changes in lipid markers and percentage variations in CPV.Results:Twenty-seven studies were selected. Correlations between percentage changes in LDL-C, non-HDL-C, and apolipoprotein B (ApoB) and percentage changes in CPV were moderate (r = 0.48, r = 0.47, and r = 0.44, respectively). Correlations between absolute differences in LDL-C, non‑HDL-C, and ApoB with percentage differences in CPV were stronger (r = 0.57, r = 0.52, and r = 0.79). The linear regression model showed a statistically significant association between a reduction in lipid markers and regression of plaque volume.Conclusion:A significant association between changes in different atherogenic particles and regression of CPV was observed. The absolute reduction in ApoB showed the strongest correlation with coronary plaque regression.

https://doi.org/10.5935/abc.20150050 2768 downloads

12.

THE TAMARA II TRIAL. SMOKING AMONG PHYSICIANS IN ARGENTINA
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Zylbersztejn, Horacio m.

; Masson, Walter m.

; Lobo, Lorenzo m.

; Manente, Diego g.

; García aurelio, Mauro J.

; Angel, adriana a.

; Mulassi, Andrés H.

; Giorgi, Mariano a.

; Rostan, María g.

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

jun 2015, Volume 83 N. 3 Pages 1 - 10

Abstract: En | Text: En | PDF: En

background: Smoking is the leading cause of preventable morbidity and death. It is important to know the characteristics of smoking habits among physicians and their attitude toward patients who smoke. Objective: The aim of this study is to investigate the prevalence of smoking among physicians in Argentina, the factors associated with tobacco consumption and their attitude toward their patients who smoke. Methods: An observational cross- sectional study was performed between June and December 2013 in Argentine physicians of dif-ferent specialties. Using a structured survey, the following variables were analyzed: associated cardiovascular risk factors, charac-teristics of tobacco consumption, smoking cessation training and the attitude toward the patient who smokes. results: 3,033 physicians were surveyed, ; 57% were men, and mean age was 41.3±12 years; 19.7% were current smokers and 21.7% were former smokers. The probability of being a smoker was higher among surgeons (OR 1.29) or physicians working at the emergency room (OR 1.41). Undergraduate and postgraduate tobacco cessation training was achieved by 36.6% and 40.8% of physicians, respectively. Young physicians, clinical specialties or private practice were associated with higher level of training. Tobacco cessation counseling was more frequent in physicians with higher level of training than physicians who smoked or surgeons. Former smokers presented higher prevalence of risk factors and cardiovascular events. Family history of smoking habit was more common in former smokers and current smokers. Conclusions: The prevalence of smoking among Argentine physicians is high. Different factors are involved in the probability of smoking, tobacco cessation training or the possibility of medical counseling. Higher level of training in smoking cessation must be provided.

124 downloads

13.

Adaptación para la Argentina y evaluación de las propiedades psicométricas del Cuestionario sobre la Dieta Restrictiva de Sodio en pacientes con insuficiencia cardíaca
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Masson, Walter

; Calderón, Gustavo

; Zeballos, Cecilia

; Lobo, Martín

; De Francesca, Salvador

; Rostan, María

; Curotto Grasiosi, Jorge

; Giorgi, Mariano

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

feb 2015, Volume 83 N. 1 Pages 21 - 27

Abstract: En Es | Text: En Es | PDF: En | PDF: Es

Background: The Dietary Sodium Restriction Questionnaire (DSRQ) is based on the theory of planned behavior. Originally developed in English, this instrument, consisting of three subscales (divided in 16 items evaluating the parameters associated with attitude relative to behavior, the subjective norm and the perceived behavioral control), identifies the factors affecting adherence to low-sodium diet in patients with congestive heart failure (CHF). Objectives: The purpose of this study was to perform the DSRQ transcultural adaptation into Spanish to be used in Argentina and assess its psychometric properties (validity and reliability). Methods: The transcultural adaptation was done with the recommended methodology (translation, synthesis, revision and back translation). Its validity was explored by principal component structure and factor analysis with factor extraction and Varimax rotation. Reliability was analyzed by internal consistency calculation (Cronbach's alpha) and the item-total scale correlation. Results: Headlines were adjusted and one question only had relevant semantic changes in the transcultural adaptation. A total of 230 CHF patients were included for the psychometric analysis. The proportion of missing data was very low (0.20%). Three factors were extracted from the main component analysis. After Varimax rotation, the items were grouped with the selected factors, matching the three original subscales. In the item-total analysis, no correlation showed a value < 0.30. Global Cronbach's alpha was 0.86 (0.89, 0.71 and 0.89 for the three subscales, of attitude relative to behavior, subjective norm and perceived behavioral control, respectively). Conclusions: We performed for the first time the DSRQ transcultural adaptation into Spanish for its use in Argentina. This version of the instrument showed adequate validity and reliability.

Introducción: El Cuestionario sobre la Dieta Restrictiva de Sodio [Dietary Sodium Restriction Questionnaire (DSRQ)] está basado en la teoría del comportamiento planificado. Originalmente desarrollado en inglés, este instrumento, compuesto por tres subescalas (en 16 ítems que evalúan los parámetros vinculados con la actitud en relación con el comportamiento, la norma subjetiva y el control comportamental percibido), identifica los factores que afectan la adhesión a la dieta hiposódica en pacientes con insuficiencia cardíaca congestiva (ICC). Objetivos: Realizar la adaptación transcultural del DSRQ en idioma español para su utilización en la Argentina y evaluar las propiedades psicométricas (validez y confiabilidad). Material y métodos: La adaptación transcultural se realizó con la metodología recomendada (traducción, síntesis, revisión y retrotraducción). La validez se determinó mediante análisis de forma y factorial de componentes principales con la extracción de factores y rotación Varimax. El análisis de la confiabilidad se efectuó mediante el cálculo de la consistencia interna (alfa de Cronbach) y la correlación ítem-total de la escala. Resultados: En la adaptación transcultural se adaptaron los encabezados y solamente una pregunta tuvo alteraciones semánticas relevantes. Para el análisis de las propiedades psicométricas se incluyeron 230 pacientes con ICC. La proporción de datos faltantes fue muy baja (0,20%). En el análisis de componentes principales se extrajeron tres factores. Luego de la rotación Varimax, los ítems se agruparon con los factores seleccionados, coincidiendo con las tres subescalas originales. En el análisis ítem-total, ninguna correlación mostró un valor < 0,30. El alfa de Cronbach global fue de 0,86 (0,89, 0,71 y 0,89 para las tres subescalas, de actitud en relación con el comportamiento, norma subjetiva y control comportamental percibido, respectivamente). Conclusiones: En nuestro trabajo se realizó por primera vez la adaptación transcultural del DSRQ al español para su utilización en la Argentina; la confiabilidad y la validez de esta versión del instrumento fueron adecuadas.

422 downloads

14.

Catéter de Swan Ganz: Opinión de expertos
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Cohen Arazi, Hernán

; Nani, Sebastián

; Giorgi, Mariano

; Guardiani, Fernando

; Caturla, Nicolás

; Benzadón, Mariano

Medicina (Buenos Aires)

Journal Metrics
- Sobre o periódico
- SciELO Analytics

aug 2014, Volume 74 N. 4 Pages 326 - 332

Abstract: En Es | Text: En Es | PDF: En | PDF: Es

Investigators have raised doubts as to the safety of the Swan Ganz catheter (SGC). In order to define the point of view of cardiologists in our country, the Argentine Society of Cardiology’s Emergency Council organized a meeting to analyze their views in different settings (non-cardiac surgery, cardiac surgery, acute coronary syndromes and heart failure) using the RAND-UCLA appropriateness method. A detailed review with the scientific evidence was sent to the experts in cardiology prior to the meeting in the SAC auditorium where the panellists selected the clinical variables create the specific situations. These hypothetic situations were resent to the panellists at a second stage for their individual evaluation, rating the benefit-to-harm ratio of the procedure on a scale of 1 to 9 (1 meant that the expected harms greatly outweighed the expected benefits, and 9 that the expected benefits greatly outweighed the expected harms, 5 could mean either that the harms and benefits were roughly equal). Two experts analyzed the results, describing the agreement/disagreement ratio. Finally, each indication was classified as “appropriate,” “uncertain” or “inappropriate” for the procedure in accordance with the panelists’ median score: median scores in the 1-3 range were classified as inappropriate, those in the 4-6 range as uncertain, and those in the 7-9 range as appropriate. We observed high disagreement rates in SGC indications between cardiologists. However, the panelists were in favor of SGC use when situations included shock and myocardial dysfunction, especially in the presence of organic dysfunction. There were some situations when panelists considered SGC not useful, in patients without organ failure.

Actualmente existen dudas sobre la seguridad del uso del catéter de Swan Ganz (CSG). Para definir la opinión de los cardiólogos de nuestro país, el Consejo de Emergencias Cardiovasculares de la Sociedad Argentina de Cardiología (SAC) realizó una reunión para evaluar la opinión de expertos en diferentes escenarios (cirugía no cardíaca, cardíaca, síndromes coronarios e insuficiencia cardíaca), usando el método RAND-UCLA appropiateness. Se envió la evidencia bibliográfica previa a la reunión en la SAC y en la misma los panelistas seleccionaron las variables para conformar las situaciones clínicas que luego fueron enviadas para que individualmente, en una segunda etapa, determinaran si consideraban beneficioso o perjudicial la utilización del catéter con una escala de 1 a 9 (1 significaba que los potenciales perjuicios superaban a los beneficios, 9 que los beneficios eran mayores y 5 que podía considerarse indistintamente beneficioso o perjudicial). Dos expertos analizaron los resultados, describiendo la tasa de acuerdo/desacuerdo. Finalmente, cada indicación se clasificó como “apropiada”, “dudosa” o inapropiada de acuerdo a la mediana definida por los panelistas: 1-3 se clasificó como inapropiado, 4-6 dudoso y 7-9 como indicación apropiada. Observamos gran discrepancia en la opinión sobre la indicación de CSG entre los expertos. Sin embargo, los panelistas estuvieron a favor de su utilización en situaciones que incluían shock y disfunción miocárdica, especialmente cuando se asoció disfunción orgánica. Hubo situaciones en las que los panelistas consideraron inapropiada la indicación del CSG, en pacientes sin disfunción orgánica.

1823 downloads

15.

Respuesta a las estatinas en prevención cardiovascular: evaluación de los hiporrespondedores
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Masson, Walter

; Lobo, Martín

; Manente, Diego

; Vitagliano, Laura

; Rostán, María

; Siniawski, Daniel

; Huerin, Melina

; Giorgi, Mariano

Revista argentina de cardiología

Journal Metrics
- Sobre o periódico
- SciELO Analytics

feb 2014, Volume 82 N. 1 Pages 34 - 41

Abstract: En Es | Text: En Es | PDF: En | PDF: Es

Introduction Numerous clinical trials have shown that statins reduce cardiovascular events, both in primary and secondary prevention. There is, however, considerable individual variation in the expected response for each dose and type of statin; therefore, detection of hypo-responder patients would allow considering additional hypolipidemic treatment. Objectives The aims of this study were to evaluate the response to statins in cardiovascular prevention patients and to analyze the characteristics of hyporesponder subjects. Methods Consecutive outpatients receiving statins were included. The treating physician defined the type and dose of statin used. The lipid profile was assessed at baseline and post-treatment (6-24 weeks). The distribution of LDL-C reduction for each type and dose of statin was analyzed and “low response” was defined according to two strategies: if the percent reduction was below the median or below the 25th percentile. Univariate and multivariate analyses were performed. Results A total of 446 patients (52% female, 25% diabetic, 80% primary prevention, age 58 ± 11 years) were included in the study. Mean LDL-C reduction was 27%, 38% and 43% for simvastatin 10, 20 and 40 mg, respectively, 36% and 43% for atorvastatin 10 and 20 mg, respectively, and 44% and 49% for rosuvastatin 10 and 20 mg, respectively. Hypores-ponsiveness defined by both strategies (median and 25th percentile) showed that male gender (OR 2.54 and 2.31), diabetes (OR 2.0 and 3.85), age (every 5 years, OR 0.87 and 0.83) and baseline LDL-C (every 10 mg/dL, OR 0.78 and 0.77) were independently associated with greater chance of being hypo-responder. Conclusions LDL-C reduction by different statins was similar to previous reports. Men, diabetics, younger subjects or with lower baseline LDL-C were more likely to show poor response to statins.

Introducción En numerosos ensayos clínicos se demostró que las estatinas reducen los eventos cardiovasculares, tanto en prevención primaria como secundaria. Sin embargo, existe una variación individual considerable en la respuesta esperada para cada dosis y tipo de estatina, por lo que detectar al paciente hiporrespondedor a las estatinas permitiría considerar un tratamiento hipolipemiante adicional. Objetivos Evaluar la respuesta a las estatinas en pacientes en prevención cardiovascular y analizar las características de los sujetos hiporrespondedores. Material y métodos Se incluyeron en forma consecutiva pacientes ambulatorios con indicación de estatinas. El médico tratante definía la estatina y la dosis utilizada. Se analizaron los valores basales y postratamiento (6-24 semanas) del perfil lipídico. Se analizó la distribución de la reducción del C-LDL para cada tipo y dosis de estatina y se definió “baja respuesta” según dos estrategias: si el porcentaje de reducción se encontraba por debajo de la mediana o por debajo del percentil 25. Se realizaron análisis univariados y multivariados. Resultados Se incluyeron 446 pacientes (52% mujeres, 25% diabéticos, 80% prevención primaria, edad 58 ± 11 años). La reducción del C-LDL promedio fue del 27%, 38% y 43% para simvastatina 10 mg, 20 mg y 40 mg, respectivamente, del 36% y 43% para atorvastatina 10 mg y 20 mg, respectivamente, y del 44% y 49% para rosuvastatina 10 mg y 20 mg, respectivamente. Definiendo hiporrespuesta por ambas estrategias (mediana y percentil 25), el sexo masculino (OR 2,54 y 2,31), la diabetes (OR 2,0 y 3,85), la edad (cada 5 años, OR 0,87 y 0,83) y el nivel basal de C-LDL (cada 10 mg/dl, OR 0,78 y 0,77) se asociaron independientemente con una chance mayor de ser hiporrespondedor. Conclusiones La reducción del C-LDL por las diferentes estatinas fue similar a lo previamente publicado. Los hombres, los diabéticos, los sujetos más jóvenes o con niveles basales más bajos de C-LDL tuvieron mayor probabilidad de mostrar baja respuesta a las estatinas.

539 downloads Cited 2 times in SciELO

Showing

itens per page

Page of 3 Next

Select one or more results

All Alphabetic

Results

Comparative chart Download CSV

Statistics of

Send result

To*

Use ; (semicolon) to insert more emails.

Send to email

This page

Selected records

All references (max. 300)

Your email

Subject

Comments

Export format:

RIS (for EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citation

CSV (for Excel, etc)

Export:

This page

Selected itens

All references (max. 2000)

Sem resultados

No documents were found for your search

Glossary and search help

You can enrich your search in a very simple way. Use the search indexes combined with the connectors (AND or OR) and specify more your search.

For example, if you want to search for articles about
cases of dengue in Brasil in 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

See below the complete list of search indexes that can be used:

Index code	Element
ti	article title
au	author
kw	article keywords
subject	subject (title words, abstract and keywords)
ab	abstract
ta	journal short title (e.g. Cad. Saúde Pública)
journal_title	journal full title (e.g. Cadernos de Saúde Pública)
la	publication language code (e.g. pt - Portuguese, es - Spanish)
type	document type
pid	publication identifier
publication_year	publication year of publication
sponsor	sponsor
aff_country	country code of the author's affiliation
aff_institution	author affiliation institution
volume	article volume
issue	article issue
elocation	elocation
doi	DOI number
issn	journal ISSN
in	SciELO colection code (e.g. scl - Brasil, col - Colômbia)
use_license	article usage license code

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

All the contents of this site www.scielo.br, except where otherwise noted, is licensed under a Creative Commons Attribution License.
more »